Hepatoprotective Effects of Thymogen Analogues in Hydrazine Hepatopathy in Rats.

Chulanova AA, Smakhtina AM, Mal GS, Bobyntsev II, Smakhtin MY, Mishina ES, Kopeykin PM, Bogomolova EG

Bulletin of experimental biology and medicine1 Apr 2025

PMID40442470DOI10.1007/s10517-025-06405-yPepBankPUB-40442470

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

1 result from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with hydrazine hepatopathy, increasing thymogen to 100 μg/kg did not further increase hepatoprotective activity.
In plain wordsIn rats with liver injury, higher-dose thymogen did not provide further liver protection compared with the lower dose.
Peptide
Thymogen (oglufanide)
Outcome
No significant changeHepatoprotective activity at higher dose
Study
ratn: not reported in source
Hydrazine hepatopathy
Comparator
Lower dose thymogen
Outcome group
Liver fat and liver function · Liver
Studied dose
100 μg/kgAs given in this study (rat).
Source sentences
Summary
Increasing the doses of thymogen (100 μg/kg) and its analogues (120 μg/kg) did not lead to further increase in their hepatoprotective activity.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied the reparative and antioxidant effects of thymogen (10 and 100 μg/kg) and its modifications in equimolar doses (12 and 120 μg/kg) obtained by attaching the amino acid D-alanine (D-Ala) to the N- or C-terminus of the peptide molecule.
Title · context
Hepatoprotective Effects of Thymogen Analogues in Hydrazine Hepatopathy in Rats.
Report a problemFND-4044247003

Studies that did not test the peptide alone4

In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymogen (oglufanide).

02AnimalNot a test of Thymogen (oglufanide) aloneAnimal study (in vivo)Efficacy outcome
In rats with hydrazine hepatopathy, lower-dose thymogen and analogue treatments inhibited lipid peroxidation.
In plain wordsIn rats with liver injury, lower-dose thymogen and analogue treatments reduced lipid peroxidation.
Peptide
Thymogen (oglufanide)
Outcome
DecreaseLipid peroxidation
Study
ratn: not reported in source
Hydrazine hepatopathy
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Administration of peptides in lower doses inhibited LPO and stimulated reparative regeneration of hepatocytes.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied the reparative and antioxidant effects of thymogen (10 and 100 μg/kg) and its modifications in equimolar doses (12 and 120 μg/kg) obtained by attaching the amino acid D-alanine (D-Ala) to the N- or C-terminus of the peptide molecule.
Title · context
Hepatoprotective Effects of Thymogen Analogues in Hydrazine Hepatopathy in Rats.
In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).
Report a problemFND-4044247001
03AnimalNot a test of Thymogen (oglufanide) aloneAnimal study (in vivo)Efficacy outcome
In rats with hydrazine hepatopathy, lower-dose thymogen and analogue treatments stimulated reparative hepatocyte regeneration.
In plain wordsIn rats with liver injury, lower-dose thymogen and analogue treatments increased liver-cell repair.
Peptide
Thymogen (oglufanide)
Outcome
IncreaseHepatocyte reparative regeneration
Study
ratn: not reported in source
Hydrazine hepatopathy
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Administration of peptides in lower doses inhibited LPO and stimulated reparative regeneration of hepatocytes.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied the reparative and antioxidant effects of thymogen (10 and 100 μg/kg) and its modifications in equimolar doses (12 and 120 μg/kg) obtained by attaching the amino acid D-alanine (D-Ala) to the N- or C-terminus of the peptide molecule.
Title · context
Hepatoprotective Effects of Thymogen Analogues in Hydrazine Hepatopathy in Rats.
In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).
Report a problemFND-4044247002
04AnimalNot a test of Thymogen (oglufanide) aloneAnimal study (in vivo)Efficacy outcome
In rats with hydrazine hepatopathy, the C-terminal D-Ala thymogen analogue was the most effective tested peptide.
In plain wordsIn rats with liver injury, the C-terminal D-Ala thymogen analogue was the most effective tested peptide.
Peptide
Thymogen (oglufanide)
Outcome
IncreaseComparative hepatoprotective effectiveness
Study
ratn: not reported in source
Hydrazine hepatopathy
Comparator
Other tested peptides
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Thymogen analogue with D-Ala at the C-terminus was most effective.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied the reparative and antioxidant effects of thymogen (10 and 100 μg/kg) and its modifications in equimolar doses (12 and 120 μg/kg) obtained by attaching the amino acid D-alanine (D-Ala) to the N- or C-terminus of the peptide molecule.
Title · context
Hepatoprotective Effects of Thymogen Analogues in Hydrazine Hepatopathy in Rats.
In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).
Report a problemFND-4044247004
05AnimalNot a test of Thymogen (oglufanide) aloneAnimal study (in vivo)Efficacy outcome
In rats with hydrazine hepatopathy, increasing thymogen analogue doses to 120 μg/kg did not further increase hepatoprotective activity.
In plain wordsIn rats with liver injury, higher doses of thymogen analogues did not increase liver protection compared with lower doses.
Peptide
Thymogen (oglufanide)
Outcome
No significant changeAnalogue hepatoprotective activity at higher doses
Study
ratn: not reported in source
Hydrazine hepatopathy
Comparator
Lower doses of thymogen analogues
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Increasing the doses of thymogen (100 μg/kg) and its analogues (120 μg/kg) did not lead to further increase in their hepatoprotective activity.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied the reparative and antioxidant effects of thymogen (10 and 100 μg/kg) and its modifications in equimolar doses (12 and 120 μg/kg) obtained by attaching the amino acid D-alanine (D-Ala) to the N- or C-terminus of the peptide molecule.
Title · context
Hepatoprotective Effects of Thymogen Analogues in Hydrazine Hepatopathy in Rats.
In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).
Report a problemFND-4044247005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.